When pharmaceutical companies such as Pfizer and GlaxoSmithKline do drug testing on new drugs and think that these new drugs are going to be great successes, they usually let their investors know and publicize this success. But what happens when the drug doesn’t work out? In the case of the drug CP-122,721, a new drug in the lucrative depression field that “offers strong efficacy with fewer of the side effects”, the Pfizer company said nothing to its investors when this drug became cancelled. Instead of